Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Linda Henry

Showing results (231-240 of 280) with videos related to

Pageof 28
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 23, 2016
Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical TrialsZobair M Younossi, Maria Stepanova, Mark Sulkowski, et al.
American Journal of Preventive Medicine|June 28, 2023
Hepatitis C Cascade of Care in the Direct-Acting Antivirals Era: A Meta-AnalysisPilar Hernandez-Con, Debbie L Wilson, Huilin Tang, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 27, 2025
Global Burden of Chronic Liver Disease and Temporal Trends: A Population-Based Analysis From 1990 to 2021 With Projections to 2050Yunyu Zhao, Yajing Bo, Jian Zu, et al.
JAMA Network Open|September 16, 2021
Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver DiseaseZobair M Younossi, Sean Felix, Thomas Jeffers, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 17, 2016
Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated CirrhosisZobair M Younossi, Maria Stepanova, Jordan Feld, et al.
Journal of Hepatology|April 11, 2023
Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 personsMichael H Le, David M Le, Thomas C Baez, et al.
Alimentary Pharmacology & Therapeutics|June 23, 2022
Meta-analysis: global prevalence, trend and forecasting of non-alcoholic fatty liver disease in children and adolescents, 2000-2021Jie Li, Audrey Ha, Fajuan Rui, et al.
Journal of Viral Hepatitis|July 6, 2018
Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infectionZobair M Younossi, Maria Stepanova, Linda Henry, et al.
Alimentary Pharmacology & Therapeutics|June 30, 2020
Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practicesZobair M Younossi, Kathleen E Corey, Naim Alkhouri, et al.
The Journal of Infectious Diseases|June 12, 2020
Development and Validation of a Risk Score for Liver Cirrhosis Prediction in Untreated and Treated Chronic Hepatitis BAn K Le, Hwai-I Yang, Ming-Lun Yeh, et al.
Pageof 28

Showing results (231-240 of 280) with videos related to

Sort By:
Pageof 28
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 23, 2016
Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical TrialsZobair M Younossi, Maria Stepanova, Mark Sulkowski, et al.
American Journal of Preventive Medicine|June 28, 2023
Hepatitis C Cascade of Care in the Direct-Acting Antivirals Era: A Meta-AnalysisPilar Hernandez-Con, Debbie L Wilson, Huilin Tang, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 27, 2025
Global Burden of Chronic Liver Disease and Temporal Trends: A Population-Based Analysis From 1990 to 2021 With Projections to 2050Yunyu Zhao, Yajing Bo, Jian Zu, et al.
JAMA Network Open|September 16, 2021
Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver DiseaseZobair M Younossi, Sean Felix, Thomas Jeffers, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 17, 2016
Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated CirrhosisZobair M Younossi, Maria Stepanova, Jordan Feld, et al.
Journal of Hepatology|April 11, 2023
Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 personsMichael H Le, David M Le, Thomas C Baez, et al.
Alimentary Pharmacology & Therapeutics|June 23, 2022
Meta-analysis: global prevalence, trend and forecasting of non-alcoholic fatty liver disease in children and adolescents, 2000-2021Jie Li, Audrey Ha, Fajuan Rui, et al.
Journal of Viral Hepatitis|July 6, 2018
Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infectionZobair M Younossi, Maria Stepanova, Linda Henry, et al.
Alimentary Pharmacology & Therapeutics|June 30, 2020
Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practicesZobair M Younossi, Kathleen E Corey, Naim Alkhouri, et al.
The Journal of Infectious Diseases|June 12, 2020
Development and Validation of a Risk Score for Liver Cirrhosis Prediction in Untreated and Treated Chronic Hepatitis BAn K Le, Hwai-I Yang, Ming-Lun Yeh, et al.
Pageof 28